Corcept Therapeutics Incorporated (NASDAQ:CORT) concluded the trading on Wednesday, Sep 16, with a fall of -0.28% from its closing price on previous day.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with nil upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review CORT stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 100% Buy for it.

According to ratings assigned by 4 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 1 of them are recommending Corcept Therapeutics Incorporated (CORT) as a Hold, while 2 are in view that stock is a Buy. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is 1, whereas none of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.

Digging deeper we become aware of the PEG ratio of the CORT stock which is currently positioned at 0. It further provides that stock’s current price level is 13.48% away from its 20-day simple moving average and is 13.71% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 56.55 while volatility remained at 7.31% over the past week which changes to 9.44% when measuring it over the past month. Beta is valued at 0.65, while measure of average true range or ATR is currently at 1.34. In predicting price targets of as low as $7 and as high as $26, analysts are in agreement on assigning the stock over the next 12 months average price target of $17.75. Stock’s current price level is -60.38% above from estimated low price target while it is 47.14% below the estimated high; and even if the CORT’s share succeeded to reach the median price of $19, then the outlook of +7.53% could come to the excitement of the investors.

In comparing Corcept Therapeutics Incorporated (CORT)’s stock with other industry players reveals that stock’s latest price change of -0.28% and that of +30.99% over the past 12 months is in competing position with that of Zoetis Inc Cl A (ZTS) which saw its stock price fell by -0.63% in the recent trading and went through an increase of 31.72% in past 12-month trading. Industry’s another major player Takeda Pharmaceutical Co. Ltd (TAK) has jumped 1.68% up in latest trading session, but over the past year has faced a rise of 7.64%, while Catalent Inc (CTLT) is also down -0.28% however its price remained floating in the green at 30.99% over the same period. Corcept Therapeutics Incorporated has a P/E ratio of 18.98 against that of Zoetis Inc Cl A’s 47.69 while Takeda Pharmaceutical Co. Ltd is showing 23.08 for the same. On the other hand, the S&P 500 Index was down -0.46% in the early deals while the Dow Jones Industrial was dealing higher at 0.13%.